Kaiser Health News, in its latest update to its campaign contributions tracking tool, reports that Senator Chris Coons, D-Delaware, received the most contributions from the pharmaceutical industry during the first half of 2019, at $103,000. Coons, together with Senator Thom Tillis, R-North Carolina, who himself received $102,000 this cycle, released a draft of a patent reform bill in May, and concerns among drug makers about the eventual passage of that bill have run high.
While the US election is more than 1 year away, drug makers on both the biosimilar and innovator sides of the industry are hoping to see their interests represented and are giving substantial sums to sitting lawmakers.
Kaiser Health News (KHN), in its latest update to its campaign contributions tracking tool, reports that Senator Chris Coons, D-Delaware, received the most contributions from the pharmaceutical industry during the first half of 2019, at $103,000.
One potential reason for that significant influx of cash is the fact that Coons, together with Senator Thom Tillis, R-North Carolina, who himself received $102,000 this cycle, released a draft of a patent reform bill in May, and concerns among drug makers about the eventual passage of that bill have run high.
The proposed legislation seeks to update the legal standard for patent eligibility and, say the senators, guard against overly broad patent claims that could be abused. The bill would change the law in response to recent Supreme Court decisions that established a test for evaluating patent eligibility, and it would explicitly define “useful” inventions that would give courts a new standard to determine whether a patent is directed toward eligible subject matter.
According to the American Bar Association (ABA), currently, the patent system is rife with uncertainty and unpredictability and creates unacceptable risks for innovators. The ABA says that it supports the Coons and Tillis reforms as a means to reduce risk to entrepreneurs. However, the Coalition Against Patent Abuse, which has members that include Blue Cross Blue Shield, the biosimilar and generic group the Association for Accessible Medicines, and America’s Health Insurance Plans, says that the bill “empowers Big Pharma at the expense of everyday Americans,” and urges Congress to reject the legislation.
KHN’s data also reveal that the drug maker that has engaged in the most spending in 4 of the past 7 election cycles is biosimilar developer Pfizer, which has given more than $8 million in total and $263,886 this cycle. Fellow biosimilar developer Mylan, which will merge with Pfizer’s Upjohn unit, increased its spending this cycle, giving $113,000, or more than it gave in the previous 2 years combined.
The Association for Accessible Medicines gave $12,500 to 8 lawmakers this cycle, while the innovator drug group Biotechnology Innovation Organization gave $102,673 to more than 50 lawmakers. Innovator drug group the Pharmaceutical Research Manufacturers of America, or PhRMA, gave $71,500 this cycle to more than 50 lawmakers.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.